These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 33008265)

  • 1. Current immunosuppressive and antifibrotic therapies of systemic sclerosis and emerging therapeutic strategies.
    Fallet B; Walker UA
    Expert Rev Clin Pharmacol; 2020 Nov; 13(11):1203-1218. PubMed ID: 33008265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine.
    Lescoat A; Varga J; Matucci-Cerinic M; Khanna D
    Expert Opin Investig Drugs; 2021 Jun; 30(6):635-652. PubMed ID: 33909517
    [No Abstract]   [Full Text] [Related]  

  • 3. Antifibrotics in systemic sclerosis.
    Martin-Lopez M; Carreira PE
    Best Pract Res Clin Rheumatol; 2021 Sep; 35(3):101671. PubMed ID: 33839046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging drugs for the treatment of scleroderma: a review of recent phase 2 and 3 trials.
    Roofeh D; Lescoat A; Khanna D
    Expert Opin Emerg Drugs; 2020 Dec; 25(4):455-466. PubMed ID: 33054463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current treatment options in systemic Sclerosis (Scleroderma).
    Stummvoll GH
    Acta Med Austriaca; 2002; 29(1):14-9. PubMed ID: 11899748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interstitial lung disease in systemic sclerosis: current and future treatment.
    Giacomelli R; Liakouli V; Berardicurti O; Ruscitti P; Di Benedetto P; Carubbi F; Guggino G; Di Bartolomeo S; Ciccia F; Triolo G; Cipriani P
    Rheumatol Int; 2017 Jun; 37(6):853-863. PubMed ID: 28063071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of systemic sclerosis-associated interstitial lung disease].
    Prasse A; Bonella F; Müller-Ladner U; Witte T; Hunzelmann N; Distler J
    Z Rheumatol; 2020 Apr; 79(3):294-303. PubMed ID: 31754786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Treatment Options in Scleroderma: Recommendations and Comprehensive Review.
    Zhao M; Wu J; Wu H; Sawalha AH; Lu Q
    Clin Rev Allergy Immunol; 2022 Apr; 62(2):273-291. PubMed ID: 33449302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Innovative antifibrotic therapies in systemic sclerosis.
    Beyer C; Distler O; Distler JH
    Curr Opin Rheumatol; 2012 May; 24(3):274-80. PubMed ID: 22450392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclophosphamide for connective tissue disease-associated interstitial lung disease.
    Barnes H; Holland AE; Westall GP; Goh NS; Glaspole IN
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD010908. PubMed ID: 29297205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular and cellular pathways as treatment targets for biologic therapies in systemic sclerosis.
    Dimitroulas T; Daoussis D; Garyfallos A; Sfikakis PP; Kitas GD
    Curr Med Chem; 2015; 22(16):1943-55. PubMed ID: 25850767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease.
    Yamasaki Y; Kuwana M
    Expert Rev Clin Immunol; 2020 Jun; 16(6):547-560. PubMed ID: 32506975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging drugs and therapeutics for systemic sclerosis.
    Lee JJ; Pope JE
    Expert Opin Emerg Drugs; 2016 Dec; 21(4):421-430. PubMed ID: 27813423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The power of the EUSTAR cohort: key findings to date and implications for management of systemic sclerosis patients.
    Benvenuti F; Zanatta E; Avouac J; Müller-Ladner U; Cozzi F; Hoffmann-Vold AM; Gabrielli A; Distler O; Matucci-Cerinic M; Allanore Y; Doria A
    Expert Rev Clin Immunol; 2020 Nov; 16(11):1065-1074. PubMed ID: 33076716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapeutic management of systemic sclerosis].
    Mouthon L; Berezné A; Poiraudeau S; Guillevin L
    Presse Med; 2006 Dec; 35(12 Pt 2):1975-82. PubMed ID: 17159724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and future perspectives on management of systemic sclerosis-associated interstitial lung disease.
    Distler O; Volkmann ER; Hoffmann-Vold AM; Maher TM
    Expert Rev Clin Immunol; 2019 Oct; 15(10):1009-1017. PubMed ID: 31566449
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug development and novel therapeutics to ensure a personalized approach in the treatment of systemic sclerosis.
    Farina N; Campochiaro C; Lescoat A; Benanti G; De Luca G; Khanna D; Dagna L; Matucci-Cerinic M
    Expert Rev Clin Immunol; 2023; 19(9):1131-1142. PubMed ID: 37366065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New therapeutic strategies for systemic sclerosis--a critical analysis of the literature.
    Zandman-Goddard G; Tweezer-Zaks N; Shoenfeld Y
    Clin Dev Immunol; 2005 Sep; 12(3):165-73. PubMed ID: 16295521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis.
    White B; Bauer EA; Goldsmith LA; Hochberg MC; Katz LM; Korn JH; Lachenbruch PA; LeRoy EC; Mitrane MP; Paulus HE
    Arthritis Rheum; 1995 Mar; 38(3):351-60. PubMed ID: 7880189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on disease-modifying antirheumatic drugs in the treatment of systemic sclerosis.
    Lin AT; Clements PJ; Furst DE
    Rheum Dis Clin North Am; 2003 May; 29(2):409-26. PubMed ID: 12841302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.